0.00
price down icon100.00%   -0.157
 
loading
Glycomimetics Inc stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month. GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
See More
Previous Close:
$0.157
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$11.00M
Revenue:
$1.16M
Net Income/Loss:
$-39.74M
P/E Ratio:
0.00
EPS:
-0.62
Net Cash Flow:
$-35.02M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
Value
$0.00
$0.00
1-Week Range:
Value
$0.00
$0.00
52-Week Range:
Value
$0.00
$0.63

Glycomimetics Inc Stock (GLYC) Company Profile

Name
Name
Glycomimetics Inc
Name
Phone
240-243-1201
Name
Address
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
Employee
26
Name
Twitter
Name
Next Earnings Date
2025-03-31
Name
Latest SEC Filings
Name
GLYC's Discussions on Twitter

Compare GLYC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GLYC
Glycomimetics Inc
0.00 11.00M 1.16M -39.74M -35.02M -0.62
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-14-25 Initiated Wedbush Outperform
Jun-25-25 Initiated Stifel Buy
Mar-21-25 Initiated Cantor Fitzgerald Overweight
Jul-26-24 Downgrade TD Cowen Buy → Hold
Dec-22-23 Initiated CapitalOne Overweight
Nov-12-21 Upgrade Jefferies Hold → Buy
Nov-14-19 Initiated ROTH Capital Buy
Aug-05-19 Downgrade Jefferies Buy → Hold
Aug-05-19 Downgrade Piper Jaffray Overweight → Neutral
Aug-05-19 Downgrade SunTrust Buy → Hold
Apr-12-19 Initiated Piper Jaffray Overweight
Dec-18-18 Initiated H.C. Wainwright Buy
Jul-26-16 Initiated SunTrust Buy
Mar-17-15 Reiterated Stifel Buy
View All

Glycomimetics Inc Stock (GLYC) Latest News

pulisher
Jul 25, 2025

What analysts say about GlycoMimetics Inc. stockUnbelievable profit margins - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

GlycoMimetics Inc. Stock Analysis and ForecastExplosive earnings growth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives GlycoMimetics Inc. stock priceLightning-fast growth - Autocar Professional

Jul 25, 2025
pulisher
Jul 23, 2025

Is GlycoMimetics Inc. a good long term investmentRapid market gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 18, 2025

LifeSci Capital Initiates Coverage of GlycoMimetics (CBIO) with Outperform Recommendation - MSN

Jul 18, 2025
pulisher
Jul 15, 2025

Why GlycoMimetics Inc. stock attracts strong analyst attentionSmart Return Focused Trading - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How GlycoMimetics Inc. stock performs during market volatility200 Percent Profit Outlook - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes GlycoMimetics Inc. stock price move sharplySmart Money Trade Setups - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Wedbush Initiates Crescent Biopharma at Outperform With $27 Price Target - MarketScreener

Jul 14, 2025
pulisher
Jun 19, 2025

GlycoMimetics (NASDAQ:CBIO) Rating Increased to Strong-Buy at Lifesci Capital - Defense World

Jun 19, 2025
pulisher
Jun 18, 2025

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Crescent Biopharma Completes Merger with GlycoMimetics - TipRanks

Jun 18, 2025
pulisher
Jun 16, 2025

Crescent Biopharma Completes Merger With GlycoMimetics - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Balance Sheet Dive: GlycoMimetics Inc (GLYC)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX

Jun 16, 2025
pulisher
Jun 16, 2025

Crescent Biopharma Completes Closing of Merger with GlycoMimetic - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million | CBIO Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Crescent Biopharma Completes Closing of Merger with - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced ... - Bluefield Daily Telegraph

Jun 16, 2025
pulisher
Jun 16, 2025

Massive $200M Biotech Deal: Crescent Biopharma Secures Funding for Cancer Breakthrough Pipeline - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

GlycoMimetics, Inc. Announces Board Changes - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

GlycoMimetics Announces Chief Executive Officer Changes - MarketScreener

Jun 16, 2025
pulisher
Jun 13, 2025

GlycoMimetics (GLYC) Trading Halt Sparks Anticipation | GLYC Sto - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

GlycoMimetics (GLYC) Trading Halt Sparks Anticipation | GLYC Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 12, 2025

GlycoMimetics (NASDAQ:GLYC) Shares to Reverse Split on Monday, June 16th - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald Comments on GlycoMimetics FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 09, 2025

Where Do Analysts Think The GlycoMimetics Inc (NASDAQ: GLYC) Is Going - Stocksregister

Jun 09, 2025

Glycomimetics Inc Stock (GLYC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):